type here...

CATEGORIES

Press Release

LATEST

1...567...12Page 6 of 12

TRENDING

EDITORS CHOICE

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

Medika Life -
The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

FDA Approves Drug Combination for Treating Mesothelioma

Medika Life -
First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers SILVER SPRING, Md., Oct. 2, 2020 /PRNewswire/ -- Today, the U.S. Food...

Wadhwani Foundation $1 Million In Grants for Covid Families in India

Medika Life -
Wadhwani Foundation Announces $1 Million In Grants To Immediately Help Indian Families Impacted By Covid-19. Donations to 10 charities and organizations will provide medical and financial assistance to patients and families to help reduce the devastating impact and slow COVID-19 spread.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories